N alterations in HbA1c had been reanalyzed with all the same network as a sensitivity evaluation, omitting the trial by Apovian et al. [10] since it incorporated fewer sufferers than the other research. The SAS GLIMMIX procedure for randomeffects mixed treatment comparison was used to model binomial data for sensitivity analyses.ResultsStudies and patient characteristicsSeven RCTs were included in the final analysis. The literature search identified six RCTs that met the trial selection criteria (Attachment two), and had been applied for the pairwise evaluation. The GetGoalS trial [20] was added to consist of one particular study presenting evidence on lixisenatide compared with placebo (Figure 1).The seven RCTs (n=3,301 patients) compared the efficacy and safety of: lixisenatide versus placebo; exenatide versus placebo or insulin glargine; and insulin glargine versus placebo or NPHinsulin in adult patients with T2DM requiring a second or thirdline treatment agent owing to inadequate glycaemic control (Table 1). Patients in all research continued taking metformin plus sulphonylurea when exenatide, lixisenatide or insulin therapy was initiated. Baseline demographic characteristics per therapy groups are summarized by study in Table 1. Mean age (range 55.Cyclopentylhydrazine hydrochloride web 09.eight years), mean HbA1c (range 7.9.7 ) and imply body mass index (BMI; 30.14.six kg/m2) have been equivalent across research. The proportion of female individuals was 29.79.0 ; imply disease duration was 7.6.9 years and mean weight was 82.301.four kg.Hypoglycaemia, weight modifications and HbA1cThe incidence of hypoglycaemia and weight change is summarized by study in Table 2. The proportion of sufferers with confirmed hypoglycaemia (definitions by plasma glucose or blood glucose values differ slightly involving research [60 to 55 mg/dL; three.4 to 3.1 mmol/L]) was larger with lixisenatide, exenatide and inGMS German Healthcare Science 2014, Vol. 12, ISSN 16125/Fournier et al.: Indirect comparison of lixisenatide versus neutral …Table 1: Baseline traits from the seven trials included for indirect comparisonGMS German Medical Science 2014, Vol. 12, ISSN 16126/Fournier et al.: Indirect comparison of lixisenatide versus neutral …sulin glargine compared with placebo, but related among exenatide and insulin glargine. The incidence of confirmed hypoglycaemia was greater with NPHinsulin compared with insulin glargine (Table two). Similar benefits had been obtained for general hypoglycaemia (Table 2). Weight changes were higher with lixisenatide (decrease), exenatide (reduce) and insulin glargine (enhance) compared with placebo, too as with exenatide (reduce) compared with insulin glargine (improve).Buy280761-97-9 Weight modifications with insulin glargine (boost) and NPHinsulin (enhance) had been similar (Table 2).PMID:23800738 Alterations in HbA1c are summarized in Table three. Baseline HbA1c parameters had been related across studies. Greater alterations in HbA1c values were observed with lixisenatide, exenatide and insulin glargine compared with placebo. Similar alterations in HbA1c parameters were observed with exenatide compared with insulin glargine and with insulin glargine compared with NPHinsulin (Table 3).Table two: The incidence of hypoglycaemia and weight alterations by studyTreatmentemergent adverse eventsThe numbers of discontinuations as a result of treatmentemergent adverse events (TEAEs) have been modest inside the numerous remedy arms of the research (minimum 0.7 , maximum 9.six ) and no clear trends across compared treatments could be observed for instance, exenatide versus placebo: 4.2 versus five.1 [10] and 9.1 ver.
